recombinant c3a Search Results


recombinant mouse c3a  (R&D Systems)
93
R&D Systems recombinant mouse c3a
Recombinant Mouse C3a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse c3a/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant mouse c3a - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
c3a  (R&D Systems)
94
R&D Systems c3a
C3a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c3a/product/R&D Systems
Average 94 stars, based on 1 article reviews
c3a - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
recombinant human c3a c5a  (Complement Technology Inc)
90
Complement Technology Inc recombinant human c3a c5a
RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and <t>C5a</t> (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.
Recombinant Human C3a C5a, supplied by Complement Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human c3a c5a/product/Complement Technology Inc
Average 90 stars, based on 1 article reviews
recombinant human c3a c5a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant c3a  (Boehringer Mannheim)
90
Boehringer Mannheim recombinant c3a
RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and <t>C5a</t> (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.
Recombinant C3a, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant c3a/product/Boehringer Mannheim
Average 90 stars, based on 1 article reviews
recombinant c3a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
purified recombinant mouse c3a  (Becton Dickinson)
90
Becton Dickinson purified recombinant mouse c3a
Anti-PD-L1 treatment leads to activation of the complement system. MC38 tumor-bearing mice (∼100 mm3) were intraperitoneally injected with anti-PD-L1 antibodies. The tumors were removed at the indicated time points (n = 5–6 mice/group). (A) <t>C3a</t> and C5a levels in homogenates from tumors and spleens were quantified by ELISA. (B) C1q and C3b/iC3b/C3c staining of tumors and spleens were quantified by IHC. (C) C3b/iC3b/C3c levels of homogenates from tumors and spleens were quantified by ELISA. One-way ANOVA (A) and Multiple t-test (C) were used to evaluate statistical significance (*p < 0.05, **p < 0.01).
Purified Recombinant Mouse C3a, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/purified recombinant mouse c3a/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
purified recombinant mouse c3a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant human c3a  (Merck KGaA)
90
Merck KGaA recombinant human c3a
Anti-PD-L1 treatment leads to activation of the complement system. MC38 tumor-bearing mice (∼100 mm3) were intraperitoneally injected with anti-PD-L1 antibodies. The tumors were removed at the indicated time points (n = 5–6 mice/group). (A) <t>C3a</t> and C5a levels in homogenates from tumors and spleens were quantified by ELISA. (B) C1q and C3b/iC3b/C3c staining of tumors and spleens were quantified by IHC. (C) C3b/iC3b/C3c levels of homogenates from tumors and spleens were quantified by ELISA. One-way ANOVA (A) and Multiple t-test (C) were used to evaluate statistical significance (*p < 0.05, **p < 0.01).
Recombinant Human C3a, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human c3a/product/Merck KGaA
Average 90 stars, based on 1 article reviews
recombinant human c3a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant human c3a  (CompTech Computer Technologies)
90
CompTech Computer Technologies recombinant human c3a
Anti-PD-L1 treatment leads to activation of the complement system. MC38 tumor-bearing mice (∼100 mm3) were intraperitoneally injected with anti-PD-L1 antibodies. The tumors were removed at the indicated time points (n = 5–6 mice/group). (A) <t>C3a</t> and C5a levels in homogenates from tumors and spleens were quantified by ELISA. (B) C1q and C3b/iC3b/C3c staining of tumors and spleens were quantified by IHC. (C) C3b/iC3b/C3c levels of homogenates from tumors and spleens were quantified by ELISA. One-way ANOVA (A) and Multiple t-test (C) were used to evaluate statistical significance (*p < 0.05, **p < 0.01).
Recombinant Human C3a, supplied by CompTech Computer Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human c3a/product/CompTech Computer Technologies
Average 90 stars, based on 1 article reviews
recombinant human c3a - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and C5a (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.

Journal: Cellular & molecular medicine: open access

Article Title: Potential Mechanisms Underlying TGF-β-mediated Complement Activation in Lung Fibrosis

doi:

Figure Lengend Snippet: RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and C5a (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.

Article Snippet: These studies used recombinant human C3a and C5a (100 nM; Complement Technology, Inc., Tyler, TX), platelet-derived TGF-β1 (2 ng/ml; Roche Diagnostics, Germany).

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay

miRNA regulation in response to TGF-β, C3a and C5a for 24 h in normal primary human SAECs.

Journal: Cellular & molecular medicine: open access

Article Title: Potential Mechanisms Underlying TGF-β-mediated Complement Activation in Lung Fibrosis

doi:

Figure Lengend Snippet: miRNA regulation in response to TGF-β, C3a and C5a for 24 h in normal primary human SAECs.

Article Snippet: These studies used recombinant human C3a and C5a (100 nM; Complement Technology, Inc., Tyler, TX), platelet-derived TGF-β1 (2 ng/ml; Roche Diagnostics, Germany).

Techniques:

Anti-PD-L1 treatment leads to activation of the complement system. MC38 tumor-bearing mice (∼100 mm3) were intraperitoneally injected with anti-PD-L1 antibodies. The tumors were removed at the indicated time points (n = 5–6 mice/group). (A) C3a and C5a levels in homogenates from tumors and spleens were quantified by ELISA. (B) C1q and C3b/iC3b/C3c staining of tumors and spleens were quantified by IHC. (C) C3b/iC3b/C3c levels of homogenates from tumors and spleens were quantified by ELISA. One-way ANOVA (A) and Multiple t-test (C) were used to evaluate statistical significance (*p < 0.05, **p < 0.01).

Journal: Oncoimmunology

Article Title: Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade

doi: 10.1080/2162402X.2017.1349587

Figure Lengend Snippet: Anti-PD-L1 treatment leads to activation of the complement system. MC38 tumor-bearing mice (∼100 mm3) were intraperitoneally injected with anti-PD-L1 antibodies. The tumors were removed at the indicated time points (n = 5–6 mice/group). (A) C3a and C5a levels in homogenates from tumors and spleens were quantified by ELISA. (B) C1q and C3b/iC3b/C3c staining of tumors and spleens were quantified by IHC. (C) C3b/iC3b/C3c levels of homogenates from tumors and spleens were quantified by ELISA. One-way ANOVA (A) and Multiple t-test (C) were used to evaluate statistical significance (*p < 0.05, **p < 0.01).

Article Snippet: Biotinylated Rat Anti-Mouse C3a (clone I87–419, BD, 2 μg/ml) was used for detection, and purified recombinant mouse C3a (BD) was used as a standard.

Techniques: Activation Assay, Injection, Enzyme-linked Immunosorbent Assay, Staining